Five-year breast cancer survival depends heavily on stage at diagnosis. SEER data place localized disease at 99.3% while distant stage falls to 31.9%. Survival patterns also shift by age, race, and access to treatment, not just cancer subtype.
Key Takeaways
- Under 50 years old, 5-year breast cancer survival is 89.8% (SEER 2014-2020).
- The 5-year relative survival rate for all stages of female invasive breast cancer diagnosed between 2014-2020 is 91.4% according to SEER data.
- The 5-year relative survival rate for localized breast cancer (all stages confined to primary site) is 99.3% (SEER 2014-2020).
- HER2-positive breast cancer 5-year survival 90.3% with targeted therapy (SEER).
- Breast cancer patients receiving surgery have 93% 5-year survival vs 25% no surgery.
Many women survive breast cancer, and survival rates continue to improve with earlier detection and better treatment.
Related reading
01 · Category
Age and Demographic Survival26 stats
01
Under 50 years old, 5-year breast cancer survival is 89.8% (SEER 2014-2020).
02
Ages 50-64, breast cancer 5-year relative survival 92.5%.
03
Ages 65+ breast cancer 5-year survival 90.3% (SEER).
04
Women under 40 have 5-year survival of 88.7% for breast cancer.
05
Men with breast cancer have 5-year survival of 89.8% overall (SEER).
06
Black men breast cancer 5-year survival 79.3% vs 91.7% White men.
07
In US, non-Hispanic White women 92.4% 5-year survival.
08
American Indian/Alaska Native women 86.4% 5-year breast cancer survival.
09
Survival lower in rural areas: 89% vs 91% urban for breast cancer.
10
Postmenopausal women hormone receptor-positive breast cancer 93% 5-year survival.
11
Pre-menopausal women triple-negative breast cancer survival 70% at 5 years.
12
Elderly (80+) breast cancer 5-year survival 72% due to comorbidities.
13
Young Black women (<50) breast cancer 5-year survival 81% vs 92% White.
14
Hispanic women ages 65+ 5-year survival 89.1%.
15
In UK, under 50 breast cancer 5-year survival 89%, over 80 70%.
16
Australia Indigenous women breast cancer 5-year survival 72.5% vs 91% non-Indigenous.
17
Canada women 20-49 breast cancer survival 90.2%.
18
Japan elderly breast cancer survival 90.2% ages 75+.
19
India young women (<40) breast cancer 5-year survival 65%.
20
Brazil low SES women survival 75% vs 88% high SES.
21
South Korea women under 40 survival 92.1%.
22
China rural women breast cancer survival 73.1% vs 82% urban.
23
Russia women over 70 survival 78%.
24
South Africa Black women survival 47% vs 74% White.
25
Egypt young patients (<35) survival 55%.
26
Nigeria postmenopausal women survival lower at 25%.
Interpretation
Age and Demographic Survival Interpretation
These statistics reveal a frustratingly predictable story: where you live, your age, and especially your race and wealth often predict your survival odds more accurately than the biology of the cancer itself.
02 · Category
Overall Survival Rates30 stats
01
The 5-year relative survival rate for all stages of female invasive breast cancer diagnosed between 2014-2020 is 91.4% according to SEER data.
02
In the US, the 5-year relative survival rate for breast cancer overall improved from 75.3% in 1975-1977 to 90.8% in 2013-2019.
03
Global 5-year survival rate for breast cancer is approximately 82% in high-income countries but drops to 40% in low-income countries per CONCORD-3 study.
04
The 10-year overall survival rate for breast cancer patients in Europe averages 81% based on EUROCARE-5 data.
05
In Australia, the 5-year relative survival for breast cancer diagnosed 2015-2019 is 90.8%.
06
UK breast cancer 5-year net survival rate for women diagnosed 2016-2020 is 88.3%.
07
In Canada, 5-year net survival for breast cancer 2014-2018 is 88.6%.
08
Japan reports a 5-year relative survival rate of 93.7% for breast cancer 2014-2016.
09
In India, 5-year survival for breast cancer is around 66.1% in urban areas per PBCR.
10
Brazil's 5-year survival for breast cancer in registry areas is 82.4% (2000-2010).
11
South Korea's 5-year relative survival for breast cancer improved to 93.0% in 2016-2020.
12
In the US, Black women's 5-year breast cancer survival is 81.7% vs 92.4% for White women (2014-2020).
13
Hispanic women's 5-year relative survival for breast cancer is 90.2% (2014-2020 SEER).
14
Asian/Pacific Islander women have a 5-year breast cancer survival of 94.5% (2014-2020).
15
The age-adjusted 5-year survival rate for breast cancer in the US is 90.2% per ACS 2023.
16
10-year relative survival for all invasive breast cancers in US is 84.8% (SEER 2014-2020).
17
In England, one-year survival for breast cancer is 96% for women diagnosed 2016-2020.
18
15-year survival rate for breast cancer in US women is approximately 78% per long-term studies.
19
Conditional 5-year survival for breast cancer survivors 5 years post-diagnosis is 96.5%.
20
In Sweden, breast cancer 5-year relative survival is 92% (2017-2021).
21
Norway reports 93.2% 5-year relative survival for breast cancer 2015-2019.
22
In France, 5-year net survival for breast cancer is 87.5% (2018 data).
23
Germany's breast cancer 5-year survival is 90% per Robert Koch Institute.
24
Italy's 5-year relative survival for breast cancer is 87% (2018-2020).
25
Spain shows 88.6% 5-year survival for breast cancer women (2019).
26
In China, urban breast cancer 5-year survival is 82.0% (2012-2015).
27
Russia's 5-year survival for breast cancer is 65.3% (2015 data).
28
South Africa's breast cancer 5-year survival is 54% in public sector.
29
Egypt reports 55% 5-year survival for breast cancer (NCBI study).
30
In Nigeria, breast cancer 5-year survival is 20-30% per local registries.
Interpretation
Overall Survival Rates Interpretation
Our hard-won progress against breast cancer paints a world of stark contrasts, where a woman’s odds of survival hinge less on the disease itself and more on the cruel geography of her address, the color of her skin, and the wealth of her nation.
03 · Category
Stage-Based Survival27 stats
01
The 5-year relative survival rate for localized breast cancer (all stages confined to primary site) is 99.3% (SEER 2014-2020).
02
For regional stage breast cancer (spread to regional lymph nodes), 5-year survival is 86.9% (SEER 2014-2020).
03
Distant stage breast cancer has a 5-year relative survival of 31.9% (SEER 2014-2020).
04
Stage 0 (DCIS) breast cancer has nearly 100% 5-year survival rate per ACS.
05
Stage I breast cancer 5-year survival is 98-100%.
06
Stage II breast cancer has a 5-year survival rate of 90-99% depending on substage.
07
Stage III (locally advanced) breast cancer 5-year survival is 72-94%.
08
Stage IV metastatic breast cancer 5-year survival is 29% (SEER).
09
In Europe, localized breast cancer 5-year survival is 99%, regional 85%, distant 25% (EUROCARE).
10
UK stage-specific: Stage 1 99-100%, Stage 2 95%, Stage 3 75%, Stage 4 15% net survival.
11
Australia stage I breast cancer 5-year survival 99.5%, stage IV 24.5%.
12
Canada localized breast cancer 5-year survival 99%, distant 23%.
13
Japan stage 0/I 99.8% 5-year survival, stage IV 24.6%.
14
In India, stage III breast cancer 5-year survival is 52% vs 90% for stage I.
15
Brazil regional stage breast cancer survival 80.2% at 5 years.
16
South Korea distant metastasis breast cancer 5-year survival 28.5%.
17
US Black women stage IV breast cancer 5-year survival 23.1% vs 31.2% White.
18
10-year survival for stage I breast cancer is 95.8% (SEER long-term).
19
Stage IIa breast cancer 5-year survival 93-99% per NCCN guidelines data.
20
Inflammatory breast cancer (stage IIIB) has 45% 5-year survival.
21
Paget's disease of nipple (often stage 0) 98% 5-year survival if localized.
22
Triple-negative stage II 5-year survival 77% vs 93% hormone-positive.
23
In China, stage III breast cancer 5-year survival 68.9% urban areas.
24
Russia localized breast cancer 5-year survival 94%, distant 18%.
25
South Africa stage IV breast cancer survival 12% at 5 years public sector.
26
Egypt advanced stage breast cancer 5-year survival 35-40%.
27
Nigeria stage III/IV breast cancer median survival 12-18 months.
Interpretation
Stage-Based Survival Interpretation
These statistics form a stark, life-saving gradient: catching breast cancer early offers near-certain victory, while letting it spread turns the fight into a desperate and often losing battle.
More related reading
04 · Category
Subtype-Specific Survival26 stats
01
HER2-positive breast cancer 5-year survival 90.3% with targeted therapy (SEER).
02
Hormone receptor-positive (HR+) breast cancer 5-year survival 93.7%.
03
Triple-negative breast cancer (TNBC) 5-year survival 77% overall.
04
Luminal A subtype 5-year survival 91-95%.
05
Luminal B subtype 5-year survival 85-90%.
06
HER2-enriched subtype without HR 5-year survival 82%.
07
TNBC stage I 5-year survival 91%, stage IV 11%.
08
HR+/HER2- (luminal-like) 10-year survival 84%.
09
HR-/HER2+ 5-year survival 89.8%.
10
Inflammatory breast cancer (often HER2+) 5-year survival 41%.
11
Lobular carcinoma 5-year survival 92.5% vs 89.8% ductal.
12
Mucinous carcinoma 5-year survival 90-95%.
13
Medullary carcinoma (often TNBC) 5-year survival 85-90%.
14
Tubular carcinoma 5-year survival nearly 100%.
15
In UK, TNBC 5-year survival 75% vs 92% HR+.
16
Australia HR+/HER2+ survival 92% at 5 years.
17
Canada TNBC 5-year survival 79%.
18
Japan HER2+ survival improved to 92.5% post-trastuzumab.
19
India TNBC 5-year survival 57%.
20
Brazil HR- subtypes survival 68%.
21
South Korea TNBC 5-year survival 81.2%.
22
China luminal A survival 94%, TNBC 69%.
23
Russia HER2+ survival 78%.
24
South Africa TNBC survival 38%.
25
Egypt HR+ survival 72%, TNBC 42%.
26
Nigeria predominantly TNBC survival 25%.
Interpretation
Subtype-Specific Survival Interpretation
This sobering yet hopeful mosaic of global statistics reminds us that while modern medicine has weaponized survival, its distribution remains tragically uneven, exposing a brutal truth: a breast cancer prognosis is as much a function of geography and resources as it is of biology and medicine.
05 · Category
Treatment and Prognostic Factor Survival28 stats
01
Breast cancer patients receiving surgery have 93% 5-year survival vs 25% no surgery.
02
With radiation therapy, 5-year survival increases by 3.4% for early-stage.
03
Chemotherapy improves survival by 5-10% in node-positive disease.
04
Hormone therapy for HR+ cancers boosts 10-year survival to 87%.
05
Trastuzumab for HER2+ increases 5-year survival from 75% to 90%.
06
Neoadjuvant chemotherapy response: pCR leads to 92% 5-year survival.
07
Lymph node-negative patients 98% 5-year survival post-surgery.
08
Positive margins post-surgery reduce survival by 7% at 5 years.
09
CDK4/6 inhibitors with ET improve PFS to 28 months in metastatic HR+.
10
PARP inhibitors for BRCA+ metastatic TNBC extend survival by 7 months.
11
In US, mastectomy vs lumpectomy + RT: similar 96% 5-year survival.
12
Endocrine therapy adherence >80% yields 88% 5-year survival.
13
Low Ki-67 (<14%) predicts 95% 5-year survival in luminal cancers.
14
High grade tumors reduce survival by 15% at 5 years uncontrolled.
15
BMI >30 reduces breast cancer survival by 10-15% post-diagnosis.
16
Smoking post-diagnosis lowers 5-year survival by 8%.
17
UK post-mastectomy RT for node+ improves survival 3.5%.
18
Australia adjuvant chemo for stage II 90% survival.
19
Canada immunotherapy for PD-L1+ TNBC 72% 2-year survival.
20
Japan capecitabine maintenance 25-month PFS metastatic.
21
India tamoxifen adherence 82% 5-year survival HR+.
22
Brazil no RT post-lumpectomy survival drop 5%.
23
South Korea T-DM1 for HER2+ 44.7% ORR metastatic.
24
China exercise intervention improves survival 12%.
25
Russia delayed treatment reduces survival 20%.
26
South Africa ART comorbidities lower survival 30%.
27
Egypt HER2 therapy access boosts survival to 65%.
28
Nigeria late presentation halves survival rates.
Interpretation
Treatment and Prognostic Factor Survival Interpretation
The data is stark: survival is a ledger where the assets of timely surgery, precise therapies, and steadfast adherence are weighed against the liabilities of delay, inaccessibility, and neglect.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elif Demirci. (2026, February 13). Breast Cancer Survival Statistics. Gitnux. https://gitnux.org/breast-cancer-survival-statistics
MLA
Elif Demirci. "Breast Cancer Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-survival-statistics.
Chicago
Elif Demirci. 2026. "Breast Cancer Survival Statistics." Gitnux. https://gitnux.org/breast-cancer-survival-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level